NASDAQ:SNPX

Synaptogenix Stock Forecast, Price & News

$7.60
-0.20 (-2.56 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.32
$8.53
50-Day Range N/A
52-Week Range
$2.60
$14.40
Volume441,035 shs
Average Volume749,556 shs
Market Capitalization$45.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter.


About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Synaptogenix (NASDAQ:SNPX) Frequently Asked Questions

What stocks does MarketBeat like better than Synaptogenix?

Wall Street analysts have given Synaptogenix a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synaptogenix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Synaptogenix's key executives?

Synaptogenix's management team includes the following people:
  • Dr. Alan J. Tuchman, CEO & Director (Age 74, Pay $184.38k)
  • Dr. Daniel L. Alkon, Pres, Chief Scientific Officer & Director (Age 79, Pay $300k)
  • Mr. Robert Weinstein, CFO, Sec. & Exec. VP (Age 61, Pay $494.64k)

Who are some of Synaptogenix's key competitors?

What is Synaptogenix's stock symbol?

Synaptogenix trades on the NASDAQ under the ticker symbol "SNPX."

How do I buy shares of Synaptogenix?

Shares of SNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synaptogenix's stock price today?

One share of SNPX stock can currently be purchased for approximately $7.60.

How much money does Synaptogenix make?

Synaptogenix has a market capitalization of $45.90 million.

How many employees does Synaptogenix have?

Synaptogenix employs 4 workers across the globe.

What is Synaptogenix's official website?

The official website for Synaptogenix is www.synaptogen.com.

Where are Synaptogenix's headquarters?

Synaptogenix is headquartered at 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036.

How can I contact Synaptogenix?

Synaptogenix's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973 242 0005 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.